Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands |
| |
Authors: | Dr. Sara Sattin Dr. Jiahui Tao Dr. Gerolamo Vettoretti Dr. Elisabetta Moroni Dr. Marzia Pennati Dr. Alessia Lopergolo Dr. Laura Morelli Dr. Antonella Bugatti Dr. Abbey Zuehlke Dr. Mike Moses Dr. Thomas Prince Dr. Toshiki Kijima Dr. Kristin Beebe Dr. Marco Rusnati Dr. Len Neckers Dr. Nadia Zaffaroni Prof. David A. Agard Prof. Anna Bernardi Dr. Giorgio Colombo |
| |
Affiliation: | 1. Dipartimento di Chimica, Università degli Studi di Milano via Golgi, 19, 20133, Milan (Italy);2. Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California, 600 16th Street, San Francisco, 94158 (USA);3. Istituto di Chimica del Riconoscimento Molecolare, CNR via Mario Bianco, 9, 20131, Milan (Italy);4. Dept. Experimental Oncology and Molecular Medicine, Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori via Amadeo, 42, 20133 Milano (Italy);5. Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia (Italy);6. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892 (USA) |
| |
Abstract: | Hsp90 is a molecular chaperone of pivotal importance for multiple cell pathways. ATP‐regulated internal dynamics are critical for its function and current pharmacological approaches block the chaperone with ATP‐competitive inhibitors. Herein, a general approach to perturb Hsp90 through design of new allosteric ligands aimed at modulating its functional dynamics is proposed. Based on the characterization of a first set of 2‐phenylbenzofurans showing stimulatory effects on Hsp90 ATPase and conformational dynamics, new ligands were developed that activate Hsp90 by targeting an allosteric site, located 65 Å from the active site. Specifically, analysis of protein responses to first‐generation activators was exploited to guide the design of novel derivatives with improved ability to stimulate ATP hydrolysis. The molecules’ effects on Hsp90 enzymatic, conformational, co‐chaperone and client‐binding properties were characterized through biochemical, biophysical and cellular approaches. These designed probes act as allosteric activators of the chaperone and affect the viability of cancer cell lines for which proper functioning of Hsp90 is necessary. |
| |
Keywords: | allostery drug design functional dynamics glycoconjugates Hsp90 |
|
|